Strides Pharma Science Limited (STAR.NS) Bundle
Born in 1990 and headquartered in Bengaluru, Strides Pharma Science Limited is rapidly scaling a global footprint-operating in over 100 countries with a diverse portfolio from tablets to controlled substances and a manufacturing footprint spanning eight facilities across four continents (including five US FDA‑approved sites) backed by a dedicated R&D centre focused on complex generics; with fiscal 2025 revenue of ₹45,653 million (a 17.2% year‑on‑year rise) and EBITDA of ₹8,028 million (up 36.8%), the company pairs a mission to expand access to high‑quality, affordable medicines with agility, care and meaningful innovation, a vision to be the leading Indian pharmaceutical multinational built on uncompromising quality and integrity, and core values-Integrity, Competency and Efficiency-that drive sustainable growth and a clear pledge to reach Net Zero by 2045.
Strides Pharma Science Limited (STAR.NS) - Intro
Strides Pharma Science Limited (STAR.NS), founded in 1990 and headquartered in Bengaluru, India, is a global pharmaceutical company focused on developing and manufacturing high-quality generic medicines for regulated and emerging markets. With a presence in over 100 countries and operations spanning eight manufacturing facilities across four continents - including five US FDA-approved sites - Strides delivers a broad product range and targets complex formulation needs through its dedicated R&D centre in Bengaluru.- Global footprint: presence in 100+ countries across regulated and emerging markets
- Manufacturing: 8 facilities across 4 continents; 5 US FDA‑approved sites
- Product portfolio: tablets, soft gelatin capsules, hard capsules, sachets, liquids, nasal sprays, topicals, controlled substances
- R&D focus: complex generics and formulation innovation at Bengaluru facility
| Metric | FY2025 | YoY Change |
|---|---|---|
| Revenue (₹ million) | 45,653 | +17.2% |
| EBITDA (₹ million) | 8,028 | +36.8% |
| Manufacturing sites | 8 (4 continents) | - |
| US FDA‑approved sites | 5 | - |
| Geographic reach | 100+ countries | - |
| Net Zero target | 2045 | - |
- To improve global access to affordable, high-quality medicines by developing and delivering safe, effective generics and specialty formulations.
- To uphold stringent quality and regulatory compliance across manufacturing and supply chains while advancing patient-centric solutions.
- To be a trusted global pharmaceutical partner recognized for complex generics, consistent supply, and innovation that addresses unmet patient needs worldwide.
- To scale sustainably, integrating environmental responsibility and operational excellence to create long-term stakeholder value.
- Quality & Compliance - unwavering commitment to international standards, reflected in five US FDA approvals and robust quality systems.
- Patient‑Centricity - design and deliver formulations that prioritize safety, accessibility, and therapeutic effectiveness.
- Innovation - invest in R&D for complex generics and differentiated dosage forms from the Bengaluru centre.
- Integrity & Transparency - ethical conduct across commercial, regulatory, and manufacturing activities.
- Sustainability - concrete targets such as Net Zero by 2045 and initiatives to reduce carbon intensity and resource use.
- Collaboration - partner with global stakeholders to expand reach across regulated and emerging markets.
- Scale regulated market footprint via US FDA‑compliant manufacturing and dossier approvals.
- Advance complex generics pipeline through targeted R&D investments in Bengaluru.
- Optimize global supply chain resilience across eight facilities to ensure continuity for customers in 100+ countries.
- Accelerate sustainability programs to meet Net Zero 2045, including energy efficiency, renewable adoption, and waste reduction.
| Indicator | FY2025 |
|---|---|
| Revenue | ₹45,653 million |
| EBITDA | ₹8,028 million |
| EBITDA growth | 36.8% YoY |
| Revenue growth | 17.2% YoY |
| Manufacturing sites | 8 (5 US FDA) |
| Countries served | 100+ |
| Net Zero target | 2045 |
Strides Pharma Science Limited (STAR.NS) - Overview
Strides Pharma Science Limited's mission centers on enhancing global access to high-quality, affordable, and effective healthcare solutions through complex generics, differentiated formulations, and operational excellence. The company positions agility, care, and meaningful innovation at the heart of its strategy to deliver sustainable growth and lasting value for patients, partners, employees, and shareholders.- Deliver complex generic and niche formulations that address unmet patient needs across regulated and emerging markets.
- Drive affordability and access by optimizing manufacturing scale, supply-chain resilience, and global distribution capabilities.
- Embed agility and speed-to-market to capitalize on abbreviated pathways and tender-based opportunities.
- Foster continuous innovation in product development, formulation technologies, and lifecycle management.
- Balance performance with purpose-pursuing sustainable, compliant growth while prioritizing patient safety and environmental stewardship.
- Create rewarding career pathways and leadership opportunities to attract and retain talent aligned with the company's growth ambitions.
- Complex generics and niche sterile/solid oral dosage strengths for regulated markets (U.S., Europe, Australia) and emerging markets (Africa, LATAM, India).
- Capacity investments in injectable and proprietary manufacturing platforms to support launches and contract manufacturing partnerships.
- Quality systems and regulatory compliance to sustain approvals and reduce recall/inspection risk.
- Selective M&A and asset acquisitions to accelerate pipeline access and geographic reach.
| KPI / Metric | Approximate Value (Most Recent Reported Period) |
|---|---|
| Annual Revenue | INR 3,200-3,800 crore (FY ~2023-24, consolidated, approximate) |
| Net Profit / PAT | INR 200-350 crore (FY ~2023-24, consolidated, approximate) |
| Market Capitalization | INR 6,000-10,000 crore (snapshot ranges mid‑2023 to mid‑2024, market dependent) |
| Total Employees | ~4,000-5,500 (global headcount across manufacturing, R&D, commercial) |
| Manufacturing Sites | 10-15 global facilities (India, Australia, Kenya, Mauritius and other contract/partner sites) |
| R&D / Regulatory Approvals (last 3 years) | Multiple abbreviated new drug applications (ANDAs), CEPs/DMFs and market authorizations across regulated markets (dozens of filings & approvals collectively) |
- Care - patient-first mindset driving product quality, safety, and ethical conduct.
- Agility - rapid decision cycles, lean project execution, and responsiveness to customer needs.
- Innovation - platform-driven product development, formulation differentiation, and lifecycle strategies.
- Integrity & Compliance - rigorous quality assurance, transparent governance, and regulatory adherence.
- Sustainability - resource efficiency, waste reduction, and socially responsible access programs.
- Partnership - long-term collaborations with wholesalers, hospitals, NGOs, and government tenders to broaden reach.
- Expanded presence in high-value regulated markets while maintaining leadership in select emerging markets.
- Improved margin profile via higher-value complex generics and specialty injectables.
- Resilient supply chains and diversified revenue streams (proprietary brands, exports, contract manufacturing).
- Enhanced shareholder returns underpinned by sustainable, compliance-driven growth.
Strides Pharma Science Limited (STAR.NS) - Mission Statement
Strides Pharma Science Limited (STAR.NS) positions its mission around delivering high-quality, affordable pharmaceuticals globally while creating stakeholder value, enabling employee growth and upholding strict ethical standards. The mission drives commercial scale-up, diversified product development (generics, injectables, specialty products), and continuous investments in manufacturing and regulatory compliance to sustain growth and leadership.- Deliver consistently high-quality medicines at competitive prices across global markets.
- Build scalable, profitable businesses quickly through targeted acquisitions, product development and manufacturing optimization.
- Operate with uncompromising integrity, compliance and quality standards across all sites and markets.
- Create value for shareholders while providing meaningful career opportunities for employees.
- Focus on innovation in dosage forms, complex generics and specialty injectables to strengthen differentiated portfolios.
Vision Statement (expanded)
Strides envisions becoming the leading Indian pharmaceutical multinational renowned for the highest quality and integrity, achieving leadership through a differentiated portfolio, global manufacturing scale and rapid business building. The vision includes:- Being a preferred supplier in regulated markets (US, EU, Australia) and emerging markets through trusted quality and reliable supply chains.
- Expanding specialized capabilities in injectables, controlled drugs and niche generics to capture higher-value segments.
- Leveraging M&A and in-house R&D to accelerate access to new geographies and therapeutic segments.
| Metric | Reported Value (latest public disclosures) | Notes / Relevance |
|---|---|---|
| Consolidated Revenue (FY) | ~₹4,000 crore | Reflects global sales across generics, injectables and specialty products |
| Net Profit (FY) | ~₹200-300 crore | Profitability influenced by product mix, one‑offs and regulatory expenses |
| Market Capitalization | ~₹6,000-9,000 crore | Subject to market movements; indicates investor valuation of growth prospects |
| Export Contribution | ~60-70% of revenue | Strong reliance on regulated and emerging markets for sales |
| Manufacturing Sites | ~10-12 global facilities | Multiple facilities in India and international footprint for regulated markets |
| Geographic Reach | 100+ countries | Global distribution across regulated and emerging markets |
| Employees | ~4,000-5,000 | R&D, manufacturing, commercial and corporate functions |
Core Values
- Quality First - uncompromising focus on product and process quality to meet global regulatory expectations.
- Integrity & Ethics - transparent governance, compliance and ethical conduct across operations.
- Customer Centricity - reliability, supply security and responsiveness to partner needs.
- Agility & Execution - rapid scaling of high-potential businesses through focused execution.
- Innovation - investing in formulation, delivery and complex generics to differentiate offerings.
- People Development - creating opportunity, learning and merit-driven progression for employees.
How Mission, Vision & Values Translate into measurable outcomes
- Regulatory approvals and inspections: Maintaining multiple approvals from regulators (USFDA, WHO, EU approvals) supports access to regulated markets.
- Portfolio differentiation: A rising share of injectables/specialty products improves margins and reduces commodity exposure.
- Capital allocation: M&A and brownfield/greenfield investments aimed at increasing capacity and expanding product offerings.
- Operational metrics: On-time delivery, batch-release compliance and reduced recall rates as KPIs tied to quality and customer trust.
Strides Pharma Science Limited (STAR.NS): Vision Statement
Strides Pharma Science Limited (STAR.NS) envisions becoming a globally respected, innovation-driven pharmaceutical company that expands affordable access to high-quality medicines while delivering sustainable value to stakeholders. The vision emphasizes scale, ethical leadership, technology-led manufacturing, and accelerated patient impact across developed and emerging markets.- Global leadership in affordable generics, specialty injectables, and regulated-market APIs
- Consistent delivery of safe, quality medicines through compliant manufacturing and supply-chain resilience
- Balanced growth through strategic inorganic deals and focused organic R&D
Mission Statement
Strides' mission is to improve patients' lives by reliably delivering quality medicines at scale, driven by the core principles of Integrity, Competency, and Efficiency (ICE). This mission is operationalized via disciplined portfolio management, customer-centric supply solutions, and investments in people, technology, and sustainable practices.- Ensure patient safety and product compliance across all markets
- Accelerate access by reducing time-to-market through agile manufacturing
- Create shareholder value through profitable growth and disciplined capital allocation
Core Values - ICE
- Integrity: Upholding ethical practices, transparency in conduct, and adherence to global regulatory norms. This fosters trust among patients, customers, regulators, and partners.
- Competency: Investing in skills, R&D, process capabilities, and quality systems to ensure teams can consistently deliver desired clinical and commercial outcomes.
- Efficiency: Emphasizing operational agility, cross-functional collaboration, and cost-effective manufacturing to deliver faster, better results-expanding access to medicines while improving margins.
| Metric | Most Recent Annual/Trailing Figures (Approx.) | Notes |
|---|---|---|
| Annual Revenue | ₹3,800-4,200 crore (~USD 460-510 mn) | Combined revenues from generics, injectables, and contract manufacturing; includes regulated and emerging markets |
| Adjusted EBITDA Margin | ~18-22% | Reflects efficiencies from manufacturing scale and product mix |
| Net Profit (PAT) | ₹250-420 crore (~USD 30-50 mn) | Subject to one-time items, currency and integration costs in acquisition years |
| Exports / Regulated Market Revenue Share | ~55-70% | Significant exposure to US, EU, and other regulated markets via injectables and APIs |
| R&D / Capex Spend | R&D: ~2-4% of revenue; Capex: ₹200-400 crore annually (variable) | Ongoing investments in facility upgrades, compliance, and product development |
| Global Footprint | Manufacturing sites: 10+; Market presence: 100+ countries | Combination of in-house facilities and strategic partnerships |
How ICE Guides Strategic Choices
- Integrity: Robust compliance programs, third-party audits, and transparent reporting underpin market approvals and customer trust.
- Competency: Targeted upskilling and R&D pipelines enable niche injectables, complex generics, and differentiated formulations.
- Efficiency: Lean manufacturing, supply-chain diversification, and selective M&A accelerate scale and margin expansion.
Sustainability and ESG Alignment
Strides integrates its ICE values into sustainability priorities-environmental stewardship, social impact, and ethical governance-by:- Reducing carbon and water intensity at manufacturing sites through efficiency projects and technology upgrades
- Expanding access programs and partnerships to reach underserved populations
- Maintaining governance frameworks to ensure ethical procurement, anti-corruption measures, and regulatory compliance
Performance Indicators Tied to Values
| Value | Key KPIs | Target / Trend |
|---|---|---|
| Integrity | Regulatory inspection outcomes, compliance incident rate | Zero major observations; downward trend in incidents |
| Competency | New product approvals, R&D cycle time, employee upskilling hours | Steady increase in approvals and reduced cycle times year-on-year |
| Efficiency | Operating margin, OEE (Overall Equipment Effectiveness), time-to-market | Marginal improvement via capacity optimization and process automation |
Strides Pharma Science Limited (STAR.NS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.